10-Q: Plus Therapeutics Reports First Quarter 2024 Results, Secures $7.25 Million in Private Placement

Sentiment:

Quarterly Report 15 May 2024 4:00 PM

Plus Therapeutics reported a net loss of $3.26 million for the first quarter of 2024, while also securing $7.25 million in a private placement to bolster its financial position.

Capital raiseThe company completed a private placement in May 2024, raising approximately $7.25 million in gross proceeds.The private placement included the issuance of shares of common stock or pre-funded warrants, along with Series A and Series B warrants to purchase additional shares.The company may receive additional gross proceeds of approximately $12.0 million if the warrants are fully exercised.

Worse than expectedThe company's net loss of $3.26 million and a significant decrease in cash reserves to $2.9 million indicate worse than expected financial performance.

Summary

Plus Therapeutics reported a net loss of $3.26 million for the three months ended March 31, 2024, compared to a net loss of $4.8 million for the same period in 2023.
The company's grant revenue increased to $1.7 million, up from $0.5 million in the prior year, primarily due to the CPRIT grant for leptomeningeal metastases (LM) research.
Research and development expenses were $2.76 million, slightly down from $2.98 million in the same period last year.
General and administrative expenses remained relatively stable at $2.21 million.
The company's cash and cash equivalents decreased to $2.9 million from $8.5 million at the end of 2023.
A private placement in May 2024 raised approximately $7.25 million in gross proceeds.
The company is developing targeted radiotherapeutics for central nervous system cancers, with lead candidate rhenium (186Re) obisbemeda in clinical trials for recurrent glioblastoma (GBM) and LM.
The company has a term loan with a remaining balance of $0.4 million, excluding a $3.2 million final payment due at maturity on June 1, 2024.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in clinical trials and funding, the significant net loss, declining cash reserves, and Nasdaq listing concerns raise significant risks and uncertainties.

Positives

Grant revenue increased significantly due to the CPRIT grant, indicating successful funding efforts.
The company secured $7.25 million in a private placement, improving its short-term liquidity.
Clinical trials for rhenium (186Re) obisbemeda are progressing, with positive interim data reported for GBM and LM.
The company acquired the CNside technology, potentially enhancing its diagnostic capabilities.
The company received a $3 million grant from the Department of Defense for pediatric brain cancer research, further supporting its pipeline.

Negatives

The company reported a net loss of $3.26 million for the quarter, indicating ongoing financial challenges.
Cash and cash equivalents decreased significantly to $2.9 million, raising concerns about short-term liquidity.
The company has a remaining term loan balance of $0.4 million, with a $3.2 million final payment due on June 1, 2024, which could strain finances.
The company received a notice from Nasdaq for not meeting the minimum stockholders' equity requirement, raising the risk of delisting.

Risks

The company's ability to continue as a going concern is in doubt due to ongoing losses and limited cash reserves.
The company may face challenges in raising additional capital to fund its operations and clinical trials.
Failure to comply with Nasdaq listing requirements could result in delisting of the company's stock.
The company's term loan obligations, including the final payment, could strain its financial resources.
Clinical trials may not yield positive results, impacting the company's ability to commercialize its products.
The company is subject to risks associated with laws or regulatory requirements, market conditions, product performance, potential litigation, and competition.

Future Outlook

The company plans to continue clinical development of its lead drug candidate, rhenium (186Re) obisbemeda, and explore additional indications. The company also intends to develop its Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM) technology for solid organ cancers. The company expects to continue to seek additional capital to fund its operations.

Management Comments

Management believes that the company's targeted radiotherapeutic platform and unique investigational drugs have the potential to overcome the disadvantages of traditional radiation therapy.
Management is committed to advancing the company's targeted radiotherapeutic technology for the benefit of cancer patients and healthcare providers worldwide.
Management believes that the alignment with the FDA on cGMP guidance will be consistent for rhenium (186Re) obisbemeda used in other clinical development programs.
Management plans to use the HCA for breakthrough therapy designation and Phase 2 and/or a pivotal or registrational Phase 3 trial.

Industry Context

The company is operating in the radiotherapeutics market, which is focused on developing targeted therapies for cancer. The company's lead candidate, rhenium (186Re) obisbemeda, is designed to address the limitations of traditional radiation therapy by delivering higher doses of radiation directly to tumors while minimizing exposure to healthy tissues. The company is also developing a novel radioembolization technology for solid organ cancers, which is a growing area of interest in the oncology field.

Comparison to Industry Standards

The company's rhenium (186Re) obisbemeda is designed to deliver up to 20 times the radiation dose compared to standard external beam radiation therapy (EBRT) for recurrent GBM, which typically delivers around 30-35 Gray.
The median overall survival (mOS) of 13 months in 15 patients with recurrent GBM in the Phase 2 study is 63% better than the current standard of care (bevacizumab monotherapy) of 8 months.
The median progression-free survival (mPFS) of 11 months in the Phase 2 study is significantly better than the standard of care at 4 months.
The company's approach of using convection-enhanced delivery (CED) and intraventricular brain catheters for drug delivery is a targeted approach compared to systemic therapies.
The company's use of a Synthetic Control Arm platform to incorporate historical clinical data into its Phase 2 clinical trial is an innovative approach to accelerate drug development.

Stakeholder Impact

Shareholders face the risk of further dilution and potential delisting from Nasdaq.
Employees may be affected by potential cost-cutting measures if the company faces financial difficulties.
Patients may benefit from the continued development of the company's targeted radiotherapeutics.
Creditors face the risk of non-payment if the company's financial situation deteriorates.

Next Steps

The company plans to continue enrollment in the ReSPECT-GBM Phase 2b dose expansion clinical trial, targeting full enrollment by the end of 2024.
The company plans to initiate dosing in Cohort 6 of the ReSPECT-LM Phase 1/2a dose escalation trial in the second quarter of 2024.
The company is planning a new multiple dosing ReSPECT-LM clinical trial in late 2024 or early 2025.
The company plans to submit a pediatric brain tumor IND to investigate the use of rhenium (186Re) obisbemeda in two pediatric brain cancers by the third quarter of 2024.
The company will continue to seek additional capital to fund its operations and clinical trials.

Key Dates

Date	Description
2015-05-29	Date of original term loan agreement.
2020-03-29	Date of NanoTx License Agreement.
2021-01-08	Date of Piramal Master Services Agreement.
2022-01-14	Date of January 2022 Distribution Agreement with Canaccord.
2022-05-16	Date of stockholder approval for Lincoln Park share issuance.
2022-08-02	Date of 2022 Purchase Agreement with Lincoln Park.
2022-08-17	Effective date of the 2022 Purchase Agreement with Lincoln Park.
2022-09-09	Date of September 2022 Distribution Agreement with Canaccord.
2022-09-19	Date of CPRIT contract.
2023-03-03	Date of Series F Preferred Stock issuance.
2023-04-20	Date of Annual Meeting of Stockholders approving reverse stock split.
2023-04-21	Date the Board determined the ratio for the reverse stock split.
2023-04-27	Date the Certificate of Amendment to the Charter was filed.
2023-05-01	Effective date of the reverse stock split.
2023-06-28	Date of tenth amendment to the Loan and Security Agreement.
2023-07-01	Effective date of additional office lease premises in Charlottesville.
2023-08-18	Second registration statement declared effective for Lincoln Park.
2023-09-07	Date of Biocept Agreement.
2023-10-31	Date the company announced the share repurchase program.
2024-03-08	Date of Nasdaq notification of non-compliance with listing rules.
2024-04-22	Date the company provided Nasdaq with its plan to achieve compliance.
2024-04-26	Date of Biocept asset purchase.
2024-05-05	Date of Securities Purchase Agreement for private placement.
2024-05-08	Date of first amendment to Securities Purchase Agreement.
2024-05-09	Closing date of the May 2024 Private Placement.
2024-06-01	Maturity date of the term loan.

Keywords

radiotherapeutics, glioblastoma, leptomeningeal metastases, rhenium-186, clinical trials, cancer, CNS, private placement, CPRIT, nanoliposomes

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.